A novel strategy to block mitotic progression for targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Mitotic progression blockade is a key strategy for inducing cancer cell death.
• Cdc20 (cell division cycle protein 20) is crucial for mitosis and its dysregulation drives cancer progression and drug resistance.
• Targeting Cdc20-APC/C offers a potential therapeutic avenue for cancer treatment.

Purpose of the Study:

• To design and evaluate a novel proteolysis targeting chimera (PROTAC) for targeted degradation of Cdc20.
• To assess the efficacy of this PROTAC in inhibiting cancer cell proliferation and overcoming drug resistance.
• To investigate the therapeutic potential of Cdc20 degradation in a preclinical cancer model.

Main Methods:

• Design of CP5V, a PROTAC molecule comprising a Cdc20 ligand and VHL binding moiety.
• Characterization of CP5V's ability to induce Cdc20 degradation via the VHL/VBC complex and proteasomal pathway.
• Evaluation of CP5V's effects on cell cycle, tumor cell killing, and tumor growth inhibition in vitro and in a human breast cancer xenograft mouse model.

Main Results:

• CP5V specifically induces ubiquitination and proteasomal degradation of Cdc20.
• CP5V treatment leads to significant inhibition of breast cancer cell proliferation.
• CP5V resensitizes Taxol-resistant breast cancer cells and suppresses tumor progression in vivo.

Conclusions:

• CP5V-mediated degradation of Cdc20 represents a viable anti-mitotic therapeutic strategy.
• Targeted protein degradation of Cdc20 holds promise for overcoming cancer drug resistance.
• CP5V demonstrates significant potential for suppressing breast tumor progression.